Skip to main content
. Author manuscript; available in PMC: 2008 Nov 1.
Published in final edited form as: Vaccine. 2007 Sep 14;25(44):7656–7663. doi: 10.1016/j.vaccine.2007.08.042

Table 5.

Proportion (%) of Subjects with Hemagglutination-Inhibition (HAI) Titers After Immunization of ≥32, 64, and 128

    H12
 H32
 B2
Group & Dosage1
 No.
 ≥32
 ≥64
 ≥128
 ≥32
 ≥64
 ≥128
 ≥32
 ≥64
 ≥128
Total Group                    
   Standard 208 48.1 21.2 8.7 91.8 71.6 49.0 57.2 24.0 8.2
   High 206 62.6* 41.7* 19.4* 94.7 84.5* 57.3 62.1 35.9* 12.6
                     
Prev Vaccine                    
   Standard 162 46.3 20.4 8.0 92.6 72.8 49.4 54.9 22.2 6.8
   High 159 59.1* 37.1* 15.1* 93.1 81.8 52.2 60.4 32.1* 10.1
                     
No Prev Vaccine                    
   Standard 46 54.3 23.9 10.9 89.1 67.4 47.8 65.2 30.4 13.0
   High 47 74.5* 57.4* 34.0* 100.0* 93.6* 74.5* 68.1 48.9 21.3
1

Prev vaccine = previously vaccinated (2 to 5 months earlier); no prev vac = no previous vaccine; standard dosage = 15 µg HA of each component; high dosage = 60 µg HA of each component

2

H1 = A/New Caledonia (H1N1), H3 = A/Wyoming (H3N2) for HAI, and A/Fujian (H3N2) for neut, B = B/Jilin

*

High dose statistically significantly greater than standard dose (see text)